Novartis struck a major licensing deal with Abogen Biosciences to bring an mRNA-encoded CD19xCD3 T-cell engager into its autoimmune pipeline, with the arrangement valued at up to $7.8 billion. Under the terms, Novartis will pay $575 million upfront for exclusive worldwide rights to ABO2203, an in vivo RNA program intended to generate the T-cell engager in the patient. Abogen could receive up to approximately $7.2 billion in additional development, regulatory, and commercial milestones if options are exercised across covered programs. Novartis framed the asset around “immune reset” via B-cell depletion, a strategy aimed at delivering durability that may differentiate from existing autoimmune modalities. Abogen CEO Bo Ying described the agreement as validation of the company’s RNA platform beyond prophylactic vaccines. This deal underscores how large-cap biopharma continues to restock pipeline exposure via China-origin innovation, while also signaling investor and scientific confidence in RNA-encoded immune engager formats that reduce the need for recombinant protein manufacturing and enable in-body production.